...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European Journal of Nuclear Medicine and Molecular Imaging >Clinical quantification of the integrin alpha v beta 6 by [F-18]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)
【24h】

Clinical quantification of the integrin alpha v beta 6 by [F-18]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)

机译：[F-18] FB-A20FMDV2正电子源肺部临床定量整合蛋白αVβ6的临床定量[F-A20FMDV2正电子和纤维化人肺（花瓣研究）

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose The RGD-integrin, alpha v beta 6, plays a role in the pathogenesis of pulmonary fibrosis through activation of transforming growth factor beta (TGF beta). This study sought to quantify expression of alpha v beta 6 in the lungs of healthy humans and subjects with pulmonary fibrosis using the alpha v beta 6-selective [F-18]FB-A20FMDV2 PET ligand. Methods [F-18]FB-A20FMDV2 PET/CT scans were performed in healthy subjects and those with fibrotic lung disease. Standard uptake values (SUV) and volume of distribution (V-T) were used to quantify alpha v beta 6 expression. In subjects with fibrotic lung disease, qualitative assessment of the relationship between alpha v beta 6 expression and the distribution of fibrosis on high resolution computed tomography was conducted. Results A total of 15 participants (6 healthy, 7 with idiopathic pulmonary fibrosis (IPF) and 2 with connective tissue disease (CTD) associated PF) were enrolled. V-T and SUV of [F-18]FB-A20FMDV2 were increased in the lungs of subjects with pulmonary fibrosis (PF) compared with healthy subjects. Geometric mean V-T (95% CI) was 0.88 (0.60, 1.29) mL/cm(3) for healthy subjects, and 1.40 (1.22, 1.61) mL/cm(3) for subjects with IPF; and SUV was 0.54 (0.36, 0.81) g/mL for healthy subjects and 1.03 (0.86, 1.22) g/mL for subjects with IPF. The IPF/healthy V-T ratio (geometric mean, (95% CI of ratio)) was 1.59 (1.09, 2.32) (probability ratio > 1 = 0.988)) and the SUV ratio was 1.91 (1.27, 2.87) (probability ratio > 1 = 0.996). Increased uptake of [F-18]FB-A20FMDV2 in PF was predominantly confined to fibrotic areas. [F-18]FB-A20FMDV2 measurements were reproducible at an interval of 2 weeks. [F-18]FB-A20FMDV2 was safe and well tolerated. Conclusions Lung uptake of [F-18]FB-A20FMDV2, a measure of expression of the integrin alpha v beta 6, was markedly increased in subjects with PF compared with healthy subjects.
机译：目的，RGD-整合蛋白，αVβ6，通过激活转化生长因子β（TGFβ）起作用在肺纤维化发病机制中起作用。本研究试图使用αVβ6选择性[F-18] FB-A20FMDV2 PET配体，量化αvβ6在健康人体的肺部和受试者中的肺纤维化的表达。方法[F-18] FB-A20FMDV2 PET / CT扫描在健康受试者和患有纤维化肺病的人中进行。标准摄取值（SUV）和分布体积（V-T）用于量化αVβ6表达。在具有纤维化肺病的受试者中，进行了对高分辨率计算断层扫描的αVβ6表达和纤维化分布的定性评估。结果共注入15名参与者（6种健康，7种健康，7例，具有结缔组织疾病（CTD）相关的PF）。与健康受试者相比，在肺纤维化（PF）的受试者的肺部肺部V-T和SUV伴随着[F-18] FB-A20FMDV2。几何平均V-T（95％CI）为健康受试者的0.88（0.60,1.29）mL / cm（3），含有IPF的受试者的1.40（1.22,1.61）ml / cm（3）;对于具有IPF的受试者，SUV为健康受试者的0.54（0.36,0.81）克/ mL，对受试者为1.03（0.86,1.22）g / ml。 IPF /健康VT比（几何平均值，比率为95％））为1.59（1.09,2.32）（概率比> 1 = 0.988）），SUV比为1.91（1.27,2.87）（概率比> 1 = 0.996）。 PF中的[F-18] FB-A20FMDV2的摄取量主要限制在纤维化区域。 [F-18] FB-A20FMDV2测量以2周的间隔再现。 [F-18] FB-A20FMDV2安全且耐受良好。结论PF与健康受试者相比，PF与PF的受试者显着增加了[F-18] FB-A20FMDV2的肺活量，其表达ααVβ6的表达明显增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号